Alcon
ALC
Market cap $42.6B

86.20 USD

-2.92

3.28%

At close Jun 13, 4:00 PM EDT

1 day

-3.28%

5 days

-1.98%

1 month

-7.56%

3 months

-0.70%

6 months

2.41%

Year to date

3.30%

1 year

-5.64%

5 years

48.75%

10 years

48.52%

About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Employees: 25,599

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 12 [Q4 2024] → 15 (+3) [Q1 2025]

13% more first-time investments, than exits

New positions opened: 79 | Existing positions closed: 70

10% more capital invested

Capital invested by funds: $22.2B [Q4 2024] → $24.5B (+$2.29B) [Q1 2025]

1% less funds holding

Funds holding: 645 [Q4 2024] → 641 (-4) [Q1 2025]

10% less repeat investments, than reductions

Existing positions increased: 196 | Existing positions reduced: 217

3.0% less ownership

Funds ownership: 53.07% [Q4 2024] → 50.07% (-3.0%) [Q1 2025]

33% less call options, than puts

Call options by funds: $226M | Put options by funds: $340M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$110

28%

upside

Avg. target

$114

32%

upside

High target

$120

39%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Needham David Saxon	28%upside $110	Buy Reiterated	14 May 2025
Keybanc Brett Fishbin	30%upside $112	Overweight Maintained	31 Mar 2025
Mizuho Anthony Petrone	39%upside $120	Outperform Maintained	28 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about ALC published over the past 30 days

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

Zacks Investment Research

Alcon Stock Rises Following the FDA Approval of TRYPTYR

FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.

Alcon Stock Rises Following the FDA Approval of TRYPTYR

US FDA approves Alcon's new dry-eye drug

Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

US FDA approves Alcon's new dry-eye drug

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more

The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses. The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses.

Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more

Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript

Alcon Inc. (NYSE:ALC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Jack Reynolds-Clark - RBC Capital Markets Graham Doyle - UBS Ryan Zimmerman - BTIG David Saxon - Needham & Company Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Anthony Petrone - Mizuho Group Tom Stephan - Stifel Brett Fishbin - KeyBanc Capital Markets Young Li - Jefferies Jeff Johnson - Baird David Adlington - JPMorgan Operator Greetings, and welcome to the Alcon First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode.

Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered

ALC ends the first quarter of 2025 on a disappointing note.

Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Zacks Investment Research

Alcon (ALC) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Alcon (ALC) Reports Q1 Earnings: What Key Metrics Have to Say

See News Rankings

Charts implemented using Lightweight Charts™